Single-arm, open-labelled, safety and tolerability of intrabronchial and nebulised bacteriophage treatment in children with cystic fibrosis and Pseudomonas aeruginosa.

MLA

Singh, Jagdev, et al. “Single-Arm, Open-Labelled, Safety and Tolerability of Intrabronchial and Nebulised Bacteriophage Treatment in Children with Cystic Fibrosis and Pseudomonas Aeruginosa.” BMJ Open Respiratory Research, vol. 10, no. 1, Jan. 2023, pp. 1–10. EBSCOhost, https://doi.org/10.1136/bmjresp-2022-001360.

APA

Singh, J., Fitzgerald, D. A., Jaffe, A., Hunt, S., Barr, J. J., Iredel, J., & Selvadurai, H. (2023). Single-arm, open-labelled, safety and tolerability of intrabronchial and nebulised bacteriophage treatment in children with cystic fibrosis and Pseudomonas aeruginosa. BMJ Open Respiratory Research, 10(1), 1–10. https://doi.org/10.1136/bmjresp-2022-001360

Chicago

Singh, Jagdev, Dominic A. Fitzgerald, Adam Jaffe, Sharon Hunt, Jeremy J. Barr, Jonathan Iredel, and Hiran Selvadurai. 2023. “Single-Arm, Open-Labelled, Safety and Tolerability of Intrabronchial and Nebulised Bacteriophage Treatment in Children with Cystic Fibrosis and Pseudomonas Aeruginosa.” BMJ Open Respiratory Research 10 (1): 1–10. doi:10.1136/bmjresp-2022-001360.